HUE035314T2 - Tiazolidindion analógok metabolikus gyulladás által mediált betegség kezelésére - Google Patents

Tiazolidindion analógok metabolikus gyulladás által mediált betegség kezelésére Download PDF

Info

Publication number
HUE035314T2
HUE035314T2 HUE15151582A HUE15151582A HUE035314T2 HU E035314 T2 HUE035314 T2 HU E035314T2 HU E15151582 A HUE15151582 A HU E15151582A HU E15151582 A HUE15151582 A HU E15151582A HU E035314 T2 HUE035314 T2 HU E035314T2
Authority
HU
Hungary
Prior art keywords
compounds
compound
ppary
pharmaceutically acceptable
treatment
Prior art date
Application number
HUE15151582A
Other languages
English (en)
Inventor
Gerard R Colca
Rolf F Kletzien
Original Assignee
Metabolic Solutions Dev Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Solutions Dev Co Llc filed Critical Metabolic Solutions Dev Co Llc
Publication of HUE035314T2 publication Critical patent/HUE035314T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (2)

  1. Tiazolidindton analógok metabolíkus gyulladás által médiák betegség kezelésére Szabadalmi igénypontok L I , számú:
    vegyidet Parkinson-kór kezelésében vagy súlyosságának enyhítésében történő alkalmazásra.
  2. 2. I. számít;
    vegyöíetet vagy gyógyászati lag elfogadható sóját tartalmazó gyógyászati készítmény Parkín-son-kór kezelésében vaav súlyosságának enyhítésében történő alkalmazásra.
HUE15151582A 2006-03-16 2007-03-14 Tiazolidindion analógok metabolikus gyulladás által mediált betegség kezelésére HUE035314T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78289406P 2006-03-16 2006-03-16

Publications (1)

Publication Number Publication Date
HUE035314T2 true HUE035314T2 (hu) 2018-05-02

Family

ID=38328199

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15151582A HUE035314T2 (hu) 2006-03-16 2007-03-14 Tiazolidindion analógok metabolikus gyulladás által mediált betegség kezelésére

Country Status (15)

Country Link
US (4) US20090143442A1 (hu)
EP (3) EP2902026B1 (hu)
JP (2) JP5269758B2 (hu)
KR (1) KR101475955B1 (hu)
CN (1) CN101454005B (hu)
AU (1) AU2007227581B2 (hu)
CA (1) CA2646207C (hu)
ES (2) ES2654908T3 (hu)
HU (1) HUE035314T2 (hu)
MX (2) MX2008011871A (hu)
NZ (1) NZ571871A (hu)
PL (2) PL2001468T3 (hu)
RU (1) RU2445957C2 (hu)
UA (1) UA96441C2 (hu)
WO (1) WO2007109024A2 (hu)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109088A2 (en) * 2006-03-16 2007-09-27 Metabolic Solutions Development Company Combinationtherapies of thiazolidinedione analogues and glucocorticoid agonists
MX2008011871A (es) 2006-03-16 2009-02-10 Metabolic Solutions Dev Compan Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica.
JP5149271B2 (ja) 2006-03-16 2013-02-20 メタボリック ソリューションズ ディベロップメント カンパニー， エルエルシー 高血圧症を処置するためならびに脂質を下げるためのチアゾリジンジオン類似体
US8304441B2 (en) 2007-09-14 2012-11-06 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic diseases
CA2699289C (en) 2007-09-14 2016-01-19 Metabolic Solutions Development Company Thiazolidinedione analogues for the treatment of hypertension
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
SG193793A1 (en) 2008-08-12 2013-10-30 Zinfandel Pharmaceuticals Inc Method of identifying disease risk factors
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
CN102791269A (zh) * 2009-12-15 2012-11-21 新陈代谢解决方案开发公司 用于治疗神经变性疾病的ppar节制性噻唑烷二酮和组合
CN102753539B (zh) 2009-12-15 2015-09-09 新陈代谢解决方案开发公司 治疗代谢性疾病的ppar-节制的噻唑烷二酮盐
EP2512471A1 (en) * 2009-12-15 2012-10-24 Metabolic Solutions Development Company LLC Ppar-sparing thiazolidinediones and combinations for the treatment of diabetes mellitus and other metabolic diseases
AU2014202074B2 (en) * 2009-12-15 2016-01-07 Cirius Therapeutics, Inc. PPAR-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
GB2477743A (en) * 2010-02-10 2011-08-17 Argenta Therapeutics Ltd Enantiomers of 5-methyl-thiazolidine-2,4-dione glitazone compounds
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
CA2796872A1 (en) * 2010-04-19 2011-10-27 Metabolic Solutions Development Company, Llc Novel synthesis for thiazolidinedione compounds
WO2011133442A1 (en) 2010-04-19 2011-10-27 Metabolic Solutions Development Company Novel synthesis for thiazolidinedione compounds
JP5851506B2 (ja) * 2010-08-10 2016-02-03 メタボリック ソリューションズ ディベロップメント カンパニー， エルエルシー チアゾリジンジオン化合物のための合成
ES2609837T3 (es) 2010-08-10 2017-04-24 Octeta Therapeutics, Llc Nueva síntesis de compuestos de tiazolidindiona
KR20180050420A (ko) 2011-01-10 2018-05-14 진판델 파마슈티컬스 인코포레이티드 알츠하이머 병 치료를 위한 방법 및 약품
WO2012114204A2 (en) * 2011-02-15 2012-08-30 Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto Methods of treating mitochondrial dysfunction
WO2012149083A1 (en) * 2011-04-28 2012-11-01 Metabolic Solutions Development Company, Llc Ppar-sparing thiazolidinediones for the treatment of kidney related diseases
KR20130015932A (ko) * 2011-08-05 2013-02-14 연세대학교 산학협력단 저용량의 치아졸리딘다이온을 포함하는 알츠하이머 병 치료용 약학조성물
WO2014046474A2 (ko) * 2012-09-21 2014-03-27 가톨릭대학교 산학협력단 메트포민을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 조성물
KR101501375B1 (ko) 2012-09-21 2015-03-10 가톨릭대학교 산학협력단 메트포민을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 조성물
EP2931274A1 (en) * 2012-12-11 2015-10-21 Metabolic Solutions Development Company LLC Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
AU2014236510A1 (en) 2013-03-14 2015-09-24 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
US9562012B2 (en) 2013-07-22 2017-02-07 Metabolic Solutions Development Company, Llc PPAR-sparing compounds for the treatment of metabolic diseases
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
HUE039555T2 (hu) * 2014-04-02 2019-01-28 Minoryx Therapeutics S L 2,4-tiazolidindion származékok központi idegrendszer rendellenességeinek kezelésében
HUE054346T2 (hu) 2016-12-01 2021-08-30 Minoryx Therapeutics S L 5-[[4-[2-[5-(1-Hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidin-2,4-dion nem-alkoholos zsírmáj-betegség kezelésére
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
GB202210503D0 (en) 2022-07-18 2022-08-31 Univ Court Univ Of Glasgow Materials and methods for treatment of chronic myeloid leukemia (CML)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
WO1985004170A1 (en) * 1984-03-21 1985-09-26 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, process for their preparation, and medicinal composition containing same
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
WO1986002073A1 (en) 1984-10-03 1986-04-10 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, process for their preparation, and pharmaceutical composition containing same
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US5167228A (en) * 1987-06-26 1992-12-01 Brigham And Women's Hospital Assessment and modification of endogenous circadian phase and amplitude
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5441971A (en) * 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
DE69231886T2 (de) * 1991-04-11 2002-03-28 Upjohn Co Thiazolidindionderivate, herstellung und anwendung
NO302471B1 (no) 1991-12-26 1998-03-09 Sankyo Co Tiazolidinforbindelser og farmasöytisk preparat
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
WO1995007694A1 (en) * 1993-09-15 1995-03-23 Sankyo Company, Limited Use of thiazolidinediones to prevent or delay onset of niddm
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
RU2158607C2 (ru) 1995-07-03 2000-11-10 Санкио Компани Лимитед Лечение артериосклероза и ксантомы
GB0030845D0 (en) * 2000-12-18 2001-01-31 Smithkline Beecham Plc Novel treatment
EP1387843B1 (en) 2001-04-26 2007-02-28 Zentiva, a.s. Method for obtaining pioglitazone as an antidiabetic agent
WO2005054213A1 (ja) * 2003-12-02 2005-06-16 Shionogi & Co., Ltd. ペルオキシソーム増殖活性化受容体アゴニスト活性を有するイソキサゾール誘導体
MX2008011871A (es) 2006-03-16 2009-02-10 Metabolic Solutions Dev Compan Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica.
WO2007109088A2 (en) 2006-03-16 2007-09-27 Metabolic Solutions Development Company Combinationtherapies of thiazolidinedione analogues and glucocorticoid agonists
JP5149271B2 (ja) 2006-03-16 2013-02-20 メタボリック ソリューションズ ディベロップメント カンパニー， エルエルシー 高血圧症を処置するためならびに脂質を下げるためのチアゾリジンジオン類似体
CA2699289C (en) 2007-09-14 2016-01-19 Metabolic Solutions Development Company Thiazolidinedione analogues for the treatment of hypertension

Also Published As

Publication number Publication date
CA2646207C (en) 2016-01-19
AU2007227581B2 (en) 2012-11-08
EP2001468A2 (en) 2008-12-17
US20120015982A1 (en) 2012-01-19
MX2008011871A (es) 2009-02-10
KR101475955B1 (ko) 2014-12-23
EP2902026B1 (en) 2017-10-04
WO2007109024A2 (en) 2007-09-27
US8389556B2 (en) 2013-03-05
EP2001468B1 (en) 2012-10-31
CA2646207A1 (en) 2007-09-27
PL2902026T3 (pl) 2018-03-30
KR20090037381A (ko) 2009-04-15
EP2486926A1 (en) 2012-08-15
CN101454005B (zh) 2013-01-02
US20150190385A1 (en) 2015-07-09
RU2445957C2 (ru) 2012-03-27
NZ571871A (en) 2011-07-29
US20130203820A1 (en) 2013-08-08
JP5269758B2 (ja) 2013-08-21
JP2009530283A (ja) 2009-08-27
WO2007109024A3 (en) 2007-11-15
AU2007227581A1 (en) 2007-09-27
UA96441C2 (ru) 2011-11-10
CN101454005A (zh) 2009-06-10
MX356584B (es) 2018-06-05
ES2397944T3 (es) 2013-03-12
PL2001468T3 (pl) 2013-03-29
US9155729B2 (en) 2015-10-13
US20090143442A1 (en) 2009-06-04
ES2654908T3 (es) 2018-02-15
ES2654908T8 (es) 2018-04-11
JP2013100371A (ja) 2013-05-23
EP2902026A1 (en) 2015-08-05
RU2008140943A (ru) 2010-04-27

Similar Documents

Publication Publication Date Title
EP2902026B1 (en) Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
EP2203433B1 (en) 5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione for use in treating diabetes
JP5149271B2 (ja) 高血圧症を処置するためならびに脂質を下げるためのチアゾリジンジオン類似体
JP5172661B2 (ja) 抗真菌剤
JP2010539171A5 (hu)
WO2011084459A1 (en) Ppar-sparing thiazolidinediones and combinations for the treatment of obesity and other metabolic diseases
JP2009530293A (ja) チアゾリジンジオン類似体およびグルココルチコイドアゴニストの併用療法
KR20130064742A (ko) 티아졸리딘디온 유사체
WO2012177956A1 (en) Ppar-sparing compounds for use in the treatment of diabetes and other metabolic diseases
WO2012178142A1 (en) Ppar-sparing compounds and combinations fort the treatment of diabetes and other metabolic diseases
AU2013200104A1 (en) Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease